LONDON, UK — Ticagrelor (Brilinta, Brilique, AstraZeneca) did not demonstrate a clinical benefit over clopidogrel in the Examining Use of Ticagrelor in Peripheral Artery Disease (EUCLID) trial, according to top-line results announced by the company.
EUCLID included 13,885 patients in 28 countries—said to be the largest cardiovascular trial exclusively involving symptomatic patients with peripheral artery disease (PAD).
Researchers evaluated whether ticagrelor 90-mg tablets twice daily showed a benefit over clopidogrel 75 mg once daily in the prevention of cardiovascular death, heart attack, or stroke.
Ticagrelor did not meet the primary end point of time to first occurrence of cardiovascular death, MI, or ischemic stroke.
Full results of the EUCLID are scheduled to be presented in November at the American Heart Association 2016 Scientific Sessions in New Orleans.
Follow Larry Hand on Twitter: @LarryHand16. For more from theheart.org, follow us on Twitter and Facebook.
Heartwire from Medscape © 2016 Medscape, LLC
Cite this: No Ticagrelor Clinical Gain vs Clopidogrel in PAD: EUCLID Top-line Results - Medscape - Oct 07, 2016.